Aptamers as Therapeutics
The Ohio State University Wexner Medical Center · Neurological Surgery · +4 more institutions
Abstract
Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual…
Citation impact
- FWCI
- 20.86
- Percentile
- 100%
- References
- 107
Authors
4- SMShahid M. NimjeeCorresponding
The Ohio State University Wexner Medical Center, Neurological Surgery
- RRRebekah R. White
Duke Medical Center, Duke University Hospital
- RCRichard C. Becker
University of Cincinnati, University of Cincinnati Medical Center
- BABruce A. Sullenger
Duke Medical Center, Duke University Hospital
Topics & keywords
- Aptamer
- Systematic evolution of ligands by exponential enrichment
- SELEX Aptamer Technique
- Computational biology
- Biology
- Medicine
- Pharmacology
- Molecular biology
- Good health and well-being